A pilot study about the efficacy of Angelica keiskei for the morbid obese patients screened with their own adipose derived stem cell.

A pilot study about the efficacy of Angelica keiskei for the morbid obese patients screened with their own adipose derived stem cell. - A pilot study about the efficacy of the supplements based on ADSC screening.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013876

Enrollment

Registered

2014-05-07

Start date

2014-05-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid obesity

Interventions

We collect the surplus adipose cell during sleeve gastorectomy in patients with morbid obesity. After the culture, Angelica keiskei is added to adipose-derived stem cell. Adiponectin increasing effe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Morbid Obese patients who were performed Sleeve gastrectomy. 2) Patients expected over 3 month-survival from the first day of this study. 3) Patients who are obtained with the prior written consent.

Exclusion criteria

Exclusion criteria: 1) Patients with food allergy 2) Patients less than 20 years old. 3) Patients judged to be inappropriate for this study from the doctor in charge.

Design outcomes

Primary

Measure	Time frame
Adiponectin	—

Secondary

Measure	Time frame
Blood lipids Nutritional indicators Body composition	—

Countries

Japan

Contacts

Public ContactAsuka Yasueda

Osaka University Graduate School of Medicine Department of Complementary and Alternative Medicine

a-yasueda@cam.med.osaka-u.ac.jp06-6879-3498

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026